Booster Vaccination Strategies for "Living With COVID-19"
Although the primary and secondary vaccination rates in Korea account for over 75% of the total population, confirmed cases of COVID-19 are dramatically increasing due to immune waning and the Omicron variant. Therefore, it is urgent to evaluate the effectiveness of booster vaccination strategies fo...
Saved in:
Main Authors: | , , |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Although the primary and secondary vaccination rates in Korea account for over 75% of the total population, confirmed cases of COVID-19 are dramatically increasing due to immune waning and the Omicron variant. Therefore, it is urgent to evaluate the effectiveness of booster vaccination strategies for living with COVID-19. In this work, we have developed an age-specific mathematical model with eight age groups and included age-specific comorbidities to evaluate the effectiveness of age-specific vaccination prioritization strategies to minimize morbidity and mortality. Furthermore, we have investigated the impacts of age-specific vaccination strategies for different vaccine supplies and non-pharmaceutical intervention levels during two periods: (1) when vaccine supply was insufficient and (2) after the emergence of the omicron variant. During the first period, the best option was to vaccinate the 30-49 year age group and the group with comorbidities to minimize morbidity and mortality, respectively. However, a booster vaccination should prioritize the 30-49 year age group to promote both minimal morbidity and mortality. Critical factors, such as vaccination speed, vaccine efficacy, and non-pharmaceutical interventions (NPIs), should be considered for effective vaccination prioritization as well. Primary, secondary vaccinations, and a booster shot vaccinations require different age prioritization strategies under different vaccination rates, vaccine efficacies, and NPI levels. |
---|---|
Item Description: | 2296-2565 10.3389/fpubh.2022.896713 |